Ignite Creation Date:
2024-05-06 @ 3:19 AM
Last Modification Date:
2024-10-26 @ 11:31 AM
Study NCT ID:
NCT02253394
Status:
TERMINATED
Last Update Posted:
2019-11-15
First Post:
2014-09-17
Brief Title:
The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study
Sponsor:
Brigham and Womens Hospital
Organization:
Brigham and Womens Hospital
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Pulmonary Arterial Hypertension |
Keywords:
| Name | View |
|---|---|
| Renal function markers creatinine and potassium | View |
| Pulmonary Arterial Hypertension PAH | View |
| Ambrisentan | View |
| Spironolactone | View |
| Selective Endothelin A ETA inhibition | View |
| Aldosterone antagonism | View |
| Cardiac output CO | View |
| Right ventricular RV function | View |
| Heart failure | View |
| Quality of life | View |
| Pro-inflammatory cytokine | View |
| Interleukin-6 IL-6 | View |
| Troponin-I | View |
| N-terminal pro-brain natriuretic peptide NT-BNP | View |
| Collagen metabolism | View |
| N-terminal procollagen type I | View |
| Collagen III | View |
| Echocardiography | View |
| WHO Functional Class | View |
| Cardiopulmonary Exercise Test with Innocor | View |
| Peak oxygen consumption pVO2 | View |
| Liver function markers ASTALT | View |